EGFR and adenocarcinoma: However, we still do not know whether that is also the case for tumors undergoing LUSC transformation, or whether in adenocarcinomas undergoing histological transformation with drivers different than EGFR, the adenocarcinoma driver gets downregulated as well.238,239 Understanding the molecular biology of transformed tumors will be key to identifying effective therapeutic targets.